

PATENTABLE SUBJECT MATTER & PATENT POLICY

INTRODUCTION TO INTELLECTUAL
PROPERTY LAW & POLICY

PROFESSOR WAGNER



Lecture Agenda

An Overview of Subject Matter Limits

Patenting Life

Patenting Algorithms

Overview of Subject Matter Limits

The Standards for Patentability

A valid patent must be . . .

- Fully and appropriately described (§ 112)
- In compliance with statutory bars (§ 102)
- Novel (§ 102)
- Nonobvious (§ 103)
- The work of the inventors (§ 116)
- Useful (§ 101)
- **Within the appropriate subject matter (§ 101)**

35 U.S.C § 101 - Inventions patentable

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title

35 U.S.C § 101 - Inventions patentable

Whoever invents or discovers any new and **useful** process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title

The Utility Requirement

35 U.S.C § 101 - Inventions patentable

Whoever invents or discovers any new and useful **process, machine, manufacture, or composition of matter**, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title

The Subject Matter Requirement

Categories of Subject Matter Limitations

"Laws of Nature"

Gravity

Relativity

Categories of Subject Matter Limitations

"Laws of Nature"

Gravity

Relativity

"Natural Phenomena"

Living Organisms

Naturally-Occurring Products

Categories of Subject Matter Limitations

"Laws of Nature"

Gravity

Relativity

"Natural Phenomena"

Living Organisms

Naturally-Occurring Products

"Abstract Ideas"

Mathematical Algorithms

Computer Software(?)

Business Models(?)

35 U.S.C § 101 - Inventions patentable

Whoever invents or discovers any new and useful **process, machine, manufacture, or composition of matter**, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title

There isn't clear support in the statute for the limits on subject matter!

**Subject Matter Limitations are a key “policy lever”
developed by the Courts.**

Subject Matter Limitations are a key “policy lever”
developed by the Courts.

The other standards for validity operate on an invention-by-invention basis; Subject Matter Limitations operate on entire categories of inventions.

Subject Matter Limitations are a key “policy lever”
developed by the Courts.

The other standards for validity operate on an invention-by-invention basis; Subject Matter Limitations operate on entire categories of inventions.

**By design, they are flexible and adaptable. This also means
unclear and uncertain!**

“Natural Phenomena”

Diamond v Chakrabarty (1980)



Man-made bacterial
organism with
applications for
cleaning oil spills.

Diamond v Chakrabarty (1980)

Claims at issue:

1. Process of producing the bacterial organism
2. Method of using the bacterial organism
3. The bacterial organism itself



Diamond v Chakrabarty (1980)

Claims at issue:

1. Process of producing the bacterial organism
2. Method of using the bacterial organism
3. The bacterial organism itself

The Patent examiner allowed claims 1 & 2, but not 3.



Diamond v Chakrabarty (1980)

35 U.S.C § 101
Inventions patentable

Whoever invents or discovers any new and useful **process, machine, manufacture, or composition of matter**, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title

A bacterial organism clearly falls within the "composition of matter" category.

And yet the examiner rejected the claim...

Diamond v Chakrabarty (1980)

On a 5-4 vote, the Court finds the claim to the organism valid.

Reasoning: this bacteria was not naturally-occurring, and thus not subject to the “natural phenomena” limitation.



Discovery vs. Invention

Chakrabarty:

Discovery \neq Patentability ... but ... Invention = Patentability

Why impose this distinction?

If I spend \$100M to discover a naturally-occurring product that cures cancer, have I benefited society less than if I had spent \$100M to invent a synthetic product with the same properties?

Discovery vs. Invention

Chakrabarty:

Discovery \neq Patentability ... but ... Invention = Patentability

Why impose this distinction?

We want to encourage new knowledge, not exploitation of existing knowledge.

We suspect that many 'discoveries' may not really be 'new' anyway.

Parke-Davis (SDNY 1911)

Claim: An "isolated and purified" version of material in adrenal glands. ("Insulin").

Held: patentable. Not a "natural phenomena" because it was isolated and purified.

Chakrabarty

Non-natural organisms
are patentable.

Parke-Davis

"Isolated and purified"
versions of natural
products and non-
natural

(Almost)
anything in the
biological area
becomes
patentable

A boom in the
bio industry?

Overpatenting
of nature?

By the early 2010s, tens of thousands of patents on segments of human DNA had been granted, with many more in the pipeline.

These were 'isolated and purified' versions of naturally-occurring DNA.

Assn of Molecular Pathologies v Myriad (2013)

Myriad obtained a patent on BRCA1 and BRCA2 genes. These genes had been found through (extensive) research to be associated with likelihood of cancer, especially breast cancer in women.

Myriad sells testing using the BRCA1/BRCA2 genetic information allowing for screening for these genes (and thus propensity for cancer).

Because of the patent, Myriad is the only provider. The costs of testing are much higher and the availability is lower.

Assn of Molecular Pathologies v Myriad (2013)

AMP (and many others) sue Myriad, arguing that the patent claims to the BRCA1/BRCA2 genes are unpatentable “natural phenomena” and thus invalid.

Assn of Molecular Pathologies v Myriad (2013)

"Isolated DNA" versus "cDNA"

1. An isolated DNA coding for a BRCA1 polypeptide ... which has the amino acid sequence ...

[DNA sequence typical of BRCA1]

2. An isolated DNA coding for a BRCA1 polypeptide ... which has the amino acid sequence ...

[cDNA sequence typical of BRCA1]

Assn of Molecular Pathologies v Myriad (2013)

“Isolated DNA” versus “cDNA”

{ According to the Supreme Court }

Isolated DNA sequences do exist in nature (except that the chemical bonds between the ends of the sequence and the rest of the genome are broken).

cDNA is synthetic: it is (typically) created in the lab, and while it performs functionally the same as natural DNA, it does not include certain non-coding nucleotides, and thus is not the same as DNA that occurs in the body.

Assn of Molecular Pathologies v Myriad (2013)

The Supreme Court's Analysis

1. Myriad's invention is unlike Chakrabarty's: there the bacterium was not natural, and had "markedly different characteristics" from natural products.
2. Here Myriad's invention does not alter the nature or function of the natural DNA.

Assn of Molecular Pathologies v Myriad (2013)

The Supreme Court's Analysis

... but ...

The Court upholds the validity of the cDNA claims:
although the function is dictated by nature, they are man-made materials and thus patentable!

Assn of Molecular Pathologies v Myriad (2013)

The Supreme Court's Analysis

... but ...

The Court upholds the validity of the cDNA claims:
although the function is dictated by nature, they are man-made materials and thus patentable!

A footnote: if cDNA claims happen to be naturally-occurring, then they are likely unpatentable.

What is Patentable?

Basic rule: man-made materials are patentable,
naturally-occurring materials are not.

1. Clearly, isolated (and purified?) natural materials are not, themselves, patentable.

What is Patentable?

Basic rule: man-made materials are patentable,
naturally-occurring materials are not.

1. Clearly, isolated (and purified?) natural materials are not, themselves, patentable.
2. Man-made mixtures/combinations of natural materials may not be enough; A look to “distinct characteristics”? Or the “process of invention”?

What is Patentable?

Basic rule: man-made materials are patentable,
naturally-occurring materials are not.

1. Clearly, isolated (and purified?) natural materials are not, themselves, patentable.
2. Man-made mixtures/combinations of natural materials may not be enough; A look to “distinct characteristics”? Or the “process of invention”?
3. However: The holding on cDNA shows that the differences between natural and man-made need not be large (or even functionally significant).

What is Patentable?

Basic rule: man-made materials are patentable,
naturally-occurring materials are not.

Is the rule of Myriad just a form of §102
(Novelty) analysis?

... and if so, then is the "natural phenomena" limitation the
right vehicle to express this concern? Why not analyze each
claim for novelty instead?

“Abstract Ideas”

Categories of Subject Matter Limitations

"Laws of Nature"

Gravity

Relativity

"Natural Phenomena"

Living Organisms

Naturally-Occurring Products


"Abstract Ideas"

Mathematical Algorithms

Computer Software(?)

Business Models(?)

The Jurisprudential Evolution of the 'Abstract Ideas' Limitation



Gottshalk v. Benson

Method to convert decimals ← binary-coded decimals unpatentable.

Diamond v. Diehr

Method to cure rubber using equation is patentable

In re Alappat

Machine using antialiasing algorithms is patentable

State Street Bank

Hub-and-spoke accounting system is patentable

AT&T v Excel

"friends and family" phone billing system is patentable

Bilski

Method to hedge commodities is unpatentable. "MOT"

Bilski

Method to hedge commodities is unpatentable.

Alice

Method to deal with intermediary risk is unpatentable.

Supreme Court

Federal Circuit

Bilski v Kappos (USSC 2010)

(Slip Opinion)

OCTOBER TERM, 2009

1

Syllabus

NOTE: Where it is feasible, a syllabus (headnote) will be released, as is being done in connection with this case, at the time the opinion is issued. The syllabus constitutes no part of the opinion of the Court but has been prepared by the Reporter of Decisions for the convenience of the reader. See *United States v. Detroit Timber & Lumber Co.*, 200 U. S. 321, 337.

SUPREME COURT OF THE UNITED STATES

Syllabus

BILSKI ET AL. *v.* KAPPOS, UNDER SECRETARY OF
COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR, PATENT AND TRADEMARK OFFICE

CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR
THE FEDERAL CIRCUIT

No. 08–964. Argued November 9, 2009—Decided June 28, 2010

Petitioners' patent application seeks protection for a claimed invention that explains how commodities buyers and sellers in the energy market can protect, or hedge, against the risk of price changes. The key claims are claim 1, which describes a series of steps instructing how to hedge risk, and claim 4, which places the claim 1 concept into a simple mathematical formula. The remaining claims explain how claims 1 and 4 can be applied to allow energy suppliers and consumers to minimize the risks resulting from fluctuations in market demand. The patent examiner rejected the application on the grounds that the invention is not implemented on a specific apparatus, merely manipulates an abstract idea, and solves a purely mathematical problem. The Board of Patent Appeals and Interferences agreed and affirmed. The Federal Circuit, in turn, affirmed. The en banc court rejected its prior test for determining whether a claimed invention was a patentable "process" under Patent Act, 35 U. S. C. §101—*i.e.*, whether the invention produced a "useful, concrete, and tangible result," see, *e.g.*, *State Street Bank & Trust Co v. Signature Financial Group, Inc.*, 149 F. 3d 1368, 1373—holding instead that a claimed process is patent eligible if: (1) it is tied to a particular machine or apparatus, or (2) it transforms a particular article into a different state or thing. Concluding that this "machine-or-transformation test" is the sole test for determining patent eligibility of a "process" under §101, the court applied the test and held that the application was not patent eligible.

Held: The judgment is affirmed.

Claims directed to a method of hedging risk in a commodity.

Unclear whether the method was novel under §102.

Federal Circuit: unpatentable because "neither a machine nor a transformation."

Bilski's claims are unpatentable abstract ideas



MOT test is not the "exclusive test," but a useful and important clue



MOT test may not be useful for "inventions in the information age," (though no suggestion for the correct test)



Business methods are not categorically excluded from patentability



The Federal Circuit could craft rules that exclude most / many business methods



Methods of doing business are not patentable
subject matter



MOT test is not the “exclusive test,” but not
many processes lie beyond its reach



Why are the claims unpatentable?

“Hedging is a fundamental economic practice long prevalent in our system of commerce and taught in any introductory finance class.”

“Allowing patents on risk hedging would pre-empt use of this approach in all fields, and would effectively grant a monopoly over an abstract idea.”

After Bilski: Confusion

Many courts and the USPTO relied heavily on the “machine or transformation” test, even though the Bilski opinion said it was not the exclusive test.

Still many patents on “algorithms” upheld: for example software patents, not involving non-novel concepts (i.e., risk hedging) or limited to computers.

Alice v CLS Bank (USSC 2014)

(Slip Opinion)

OCTOBER TERM, 2013

1

Syllabus

NOTE: Where it is feasible, a syllabus (headnote) will be released, as is being done in connection with this case, at the time the opinion is issued. The syllabus constitutes no part of the opinion of the Court but has been prepared by the Reporter of Decisions for the convenience of the reader. See *United States v. Detroit Timber & Lumber Co.*, 200 U. S. 321, 337.

SUPREME COURT OF THE UNITED STATES

Syllabus

ALICE CORPORATION PTY. LTD. *v.* CLS BANK
INTERNATIONAL ET AL.

CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR
THE FEDERAL CIRCUIT

No. 13–298. Argued March 31, 2014—Decided June 19, 2014

Petitioner Alice Corporation is the assignee of several patents that disclose a scheme for mitigating “settlement risk,” *i.e.*, the risk that only one party to an agreed-upon financial exchange will satisfy its obligation. In particular, the patent claims are designed to facilitate the exchange of financial obligations between two parties by using a computer system as a third-party intermediary. The patents in suit claim (1) a method for exchanging financial obligations, (2) a computer system configured to carry out the method for exchanging obligations, and (3) a computer-readable medium containing program code for performing the method of exchanging obligations.

Respondents (together, CLS Bank), who operate a global network that facilitates currency transactions, filed suit against petitioner, arguing that the patent claims at issue are invalid, unenforceable, or not infringed. Petitioner counterclaimed, alleging infringement. After *Bilski v. Kappos*, 561 U. S. 593, was decided, the District Court held that all of the claims were ineligible for patent protection under 35 U. S. C. §101 because they are directed to an abstract idea. The en banc Federal Circuit affirmed.

Held: Because the claims are drawn to a patent-ineligible abstract idea, they are not patent eligible under §101. Pp. 5–17.

(a) The Court has long held that §101, which defines the subject matter eligible for patent protection, contains an implicit exception for “[l]aws of nature, natural phenomena, and abstract ideas.” *Association for Molecular Pathology v. Myriad Genetics, Inc.*, 569 U. S. ___, ___. In applying the §101 exception, this Court must distinguish patents that claim the “buildin[g] block[s]” of human ingenuity, which are ineligible for patent protection, from those that integrate

Claims directed to a method of addressing counterparty risk in financial transactions, using a trusted intermediary.

Unclear whether the method was novel under §102.

Federal Circuit: unpatentable, but barely (and split)

The (New) Framework for 'Abstract Ideas'

Step 1: Are the claims directed to an "abstract idea"?

Step 2: if so, "what more is in the claims" to avoid the limitation?

Alice Step 1: Is this an abstract idea?

The Court answers 'yes': the idea of the claims is 'intermediated settlement'.

How do you know which claims are "abstract" and which are not?

The Court says: "on their face, the claims before us are drawn to the concept of intermediated settlement, i.e., the use of a third party to mitigate settlement risk.... [T]he concept of intermediated settlement is a fundamental economic practice long prevalent in our system of commerce."

Alice Step 1: Is this an abstract idea?

The Court answers 'yes': the idea of the claims is 'intermediated settlement'.

How do you know which claims are "abstract" and which are not?

The Court says: "on their face, the claims before us are drawn to the concept of intermediated settlement, i.e., the use of a third party to mitigate settlement risk.... [T]he concept of intermediated settlement is a fundamental economic practice long prevalent in our system of commerce."

Novelty? Or analogy (to Bilski)?

Alice Step 2: "What Else is There"?

Here the Court says that "generic computer implementation" does not "transform" the claims into patentable subject matter.

What else is required?

Mayo

adding conventional measuring steps known in the art is not enough

unpatentable

Flook

adding conventional computer-implemented steps known in the art is not enough

unpatentable

Benson

adding computer-implemented steps is not enough

unpatentable

Diehr

the addition of a thermocouple to record measurements was an inventive application of the idea

patentable

Alice Step 2: “What Else is There”?

Here the Court says that “generic computer implementation” does not “transform” the claims into patentable subject matter.

What else is required?

Does this mean that all software-based patent claims are invalid!?

Unclear. Software methods that are either “new” (Step 1) or involve an “inventive application” of the method (Step 2) are seemingly okay.

The Abstract Ideas Limitation

Bilski seems to have been bypassed.

Step 1 is a focus on “have we seen this before” /
analogy / (maybe) novelty.

Step 2 is focused on something more: “inventiveness”?

The Convergence of Patentable Subject Matter Limits

The Supreme Court seems mostly concerned with

The newness of the category of subject matter.

The breadth of the resulting patents in that category.

The Convergence of Patentable Subject Matter Limits

Myriad (2013)

A focus on the man-made
versus natural distinction.

Alice (2014)

A focus on the “newness”
versus “old” distinction.

An analysis of what more the
invention does.

Ongoing Questions about Subject Matter Limitations

If Subject Matter Limitations are simply about policy,
what, exactly, is the policy concern?

(And ... might these concerns be better addressed invention—by-invention?)

Ongoing Questions about Subject Matter Limitations

If Subject Matter Limitations are simply about policy,
what, exactly, is the policy concern?

(And ... might these concerns be better addressed invention—by-invention?)

**Are the courts (the Supreme Court) the right
institution to make these policy decisions?**